Contact us
Young GI
Patients
Industry
Press
My Connect
Create myUEG account
About
To landing page
Who we are
Boards, Committees & Groups
Governance
Headquarters Management
History
What we do
Strategic Drivers
Year in Review
Our Members
Specialist Member Societies
National Member Societies
myUEG Community
myUEG Associates
My Connect
Women in GI
Young GIs
Researchers
Event Calendar
Week
To landing page
Attendance
Registration fees
Hotel
Venue
Helpful info
Travel info
Programme
Abstract Submission
Postgraduate Teaching
Nurse Programme
Hands-on
Information for Presenters
In-person Networking
myUEG Community Area
Learn from Leaders
Mentoring
The UEG Night
Let's Meet
Women in GI Networking
Industry Programme
Industry Exhibition
Industry Symposia
Meet the experts sessions
Innovation Hub
List of Supporters & Exhibitors
CME Accreditation
UEG Week on-demand
Future UEG Weeks
Education
To landing page
Online Education
Online Courses
Webinars
Career Development
Face-to-face Education
Summer School
Masterclass
Clinical Visiting Fellowships
Education Resources
Mistakes in...
UEG Talks Podcast
Image Hub
CME in Europe
Event Endorsement
Supporters
Research
To landing page
Support
Horizon Europe Support
Start-up Grant
Research Prize
Research Fellowship
Research Webinars
Research Projects
HoloSurge
Position Papers
White Book 2
Main Results
Full Reports
Materials and Presentations
Quality of Care
To landing page
Search Guidelines
Standards & Guidelines Repository
Non-English Guidelines
GI Guidelines App
Develop & Implement
How to develop guidelines
Guideline Endorsement
Guideline Webinars
Projects
Quality of Care Initiatives
Quality Standards
Public Affairs
To landing page
Advocacy
Core Positions
Stakeholder Collaboration
White Book 2
Position Papers
MEP Digestive Health Group
Our Supporters
#EUNewsline →
EU Elections 2024
Publications
To landing page
Publications
Congress Publications
Research Publications
Public Affairs Publications
Education Publications
UEG Publications
UEG Journal →
UEG Journal Podcast
White Book 2
Opportunities
To landing page
Congress Opportunities
Top Abstract Prizes
National Scholar Award
Travel Grants
International Scholarship Awards
Research Funding
Research Prize
Research Fellowship
Horizon Europe Support
Start-up Grant
Activities Funding
Recognition of Achievements
Lifetime Achievement Award
Journal Best Paper Award
Activities Endorsement
Professional Advancement
Rising Star Awards
Clinical Visiting Fellowships
Open Positions
Talent Pool
Library
To landing page
Congress Resources
UEG Week on-demand
Abstracts
Posters
Guideline Resources
Education Resources
Image Hub
Webinars
Mistakes in... articles
Contact us
Young GI
Patients
Industry
Press
Author
Silvio Danese
A CASE OF POST-GASTRECTOMY ANASTOMOTIC LEAKAGE REFRACTORY TO ENDOSCOPIC VACUUM THERAPY, SAVED BY COVERED ESOPHAGEAL STENTING
Silvio Danese
et al.
INVESTIGATING THE ROLE OF GUT EUKARYOTIC VIROME IN CONTRIBUTING TO COLORECTAL CANCER CARCINOGENESIS
Silvio Danese
et al.
THE ROLE OF MFSD2A IN THE RESOLUTION OF COLORECTAL CANCER-PROMOTING INFLAMMATION: IMPLICATIONS FOR INNOVATIVE THERAPIES
Silvio Danese
et al.
EFFECT OF MIRIKIZUMAB ON CLINICAL AND ENDOSCOPIC OUTCOMES BASED ON PRIOR ADVANCED THERAPY FAILURE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Silvio Danese
et al.
BENEFIT OF PROLONGED FILGOTINIB DOSING IN PATIENTS WITH ULCERATIVE COLITIS WHO DID NOT RESPOND TO INDUCTION THERAPY: DATA FROM THE SELECTION LONG-TERM EXTENSION STUDY
Silvio Danese
et al.
EFFICACY AND SAFETY OF ETRASIMOD IN PATIENTS WITH MODERATE TO SEVERE ISOLATED PROCTITIS RELATIVE TO THOSE WITH MORE EXTENSIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
Silvio Danese
et al.
THE CAUDOVIRALES CLASS OF VIRUSES IS ASSOCIATED WITH DENDRITIC CELL IMPAIRMENT IN CD PATIENTS
Silvio Danese
et al.
HIGHER VS STANDARD ADALIMUMAB INDUCTION AND MAINTENANCE TREATMENT IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: INTEGRATED RESULTS FROM THE PHASE 3 SERENE-UC STUDY
Silvio Danese
et al.
ENDOSCOPIC VACUUM THERAPY (EVT) VERSUS SELF-EXPANDING METAL STENT (SEMS) IN THE TREATMENT OF NON-LARGE ANASTOMOTIC DEHISCENCES AFTER ONCOLOGIC IVOR-LEWIS ESOPHAGECTOMY: A MATCHED CASE-CONTROL STUDY
Silvio Danese
et al.
THERAPEUTIC DRUG MONITORING DOSING REGIMEN WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE SERENE-UC MAINTENANCE STUDY
Silvio Danese
et al.
BASELINE SERUM BIOMARKERS PREDICT CLINICAL EFFICACY AND TISSUE MOLECULAR RESPONSE TO INDUCTION THERAPY WITH RITLECITINIB, AN ORAL JAK3/TEC INHIBITOR, IN ULCERATIVE COLITIS (UC) (PHASE 2B VIBRATO STUDY)
Silvio Danese
et al.
EFFICACY AND SAFETY OF ADVANCED ORAL THERAPIES FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
Silvio Danese
et al.
A CHALLENGING CASE OF DILATION-ASSISTED FULL THICKNESS RESECTION THROUGH A STOMIA OF A COLONIC RESIDUAL POST-MUCOSECTOMY SCAR
Silvio Danese
et al.
EARLY ACHIEVEMENT OF PARTIAL MAYO SCORE REMISSION AND IBDQ NORMALIZATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY
Silvio Danese
et al.
TREATMENT BENEFITS OF UPADACITINIB BASED ON DISEASE SEVERITY, DISEASE DURATION AND NUMBER OF PRIOR BIOLOGICS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A POST-HOC ANALYSIS OF PHASE 3 TRIAL DATA
Silvio Danese
et al.
TARGET ENGAGEMENT AND PHARMACODYNAMIC MOLECULAR MECHANISM EVALUATION IN A PHASE 1B STUDY OF THE NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN, LEUCINE RICH REPEAT CONTAINING X1 (NLRX1) AGONIST NX-13 IN ULCERATIVE COLITIS
Silvio Danese
et al.
RELATIONSHIP BETWEEN HISTO-ENDOSCOPIC MUCOSAL HEALING AND BASELINE CHARACTERISTICS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS RECEIVING FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY
Silvio Danese
et al.
EFFECT OF OZANIMOD TREATMENT AND DISCONTINUATION ON ABSOLUTE LYMPHOCYTE COUNT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A PHASE 3 RANDOMIZED TRIAL
Silvio Danese
et al.
THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 12 INTERIM ANALYSES FROM THE PHASE 2 GALAXI 1 STUDY
Silvio Danese
et al.
RISANKIZUMAB VERSUS USTEKINUMAB FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE STUDY
Silvio Danese
et al.
Item 101 - 120 / 148
1
2
3
4
5
6
7
8
Chat with us
, powered by
LiveChat